Skip to main
BIIB

Biogen (BIIB) Stock Forecast & Price Target

Biogen (BIIB) Analyst Ratings

Based on 22 analyst ratings
Buy
Strong Buy 41%
Buy 23%
Hold 32%
Sell 5%
Strong Sell 0%

Bulls say

Biogen is a established biopharmaceutical company with a diverse portfolio of drugs targeting neurodegenerative and rare diseases. Positive clinical trial data and increased usage of blood-based diagnostics have led to an upgrade to a Buy rating and potential sales of over $7 billion. The company's estimated peak sales for Leqembi is $2 billion and they are considered a sustainability model in the industry, but face risks such as competition and pricing pressure.

Bears say

Biogen is facing several headwinds, including a declining multiple sclerosis franchise, with its newer franchises still in early stages of development and not expected to contribute significantly to revenue growth in the next few years. The recently announced data for BIIB080 and discontinuation of development of BIIB122 add to the uncertainty surrounding Biogen's pipeline. European NMD-ARO prices cannibalizing US Spinraza sales along with biosimilar competition are also looming threats for the company's top line.

Biogen (BIIB) has been analyzed by 22 analysts, with a consensus rating of Buy. 41% of analysts recommend a Strong Buy, 23% recommend Buy, 32% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Biogen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Biogen (BIIB) Forecast

Analysts have given Biogen (BIIB) a Buy based on their latest research and market trends.

According to 22 analysts, Biogen (BIIB) has a Buy consensus rating as of Jul 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $216.77, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $216.77, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Biogen (BIIB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.